drugset / Trial / NCT00197236

Immunogenicity and Safety of Havrix™ Co-Administered With a Diphtheria, Tetanus and Pertussis and a Haemophilus b Vaccine in Children Aged 15 Months

NCT00197236

Phase 3 Completed 468 enrolled GlaxoSmithKline
RandomizedParallel-groupOpen-labelPrevention

Summary

This is a study to evaluate the immune response and safety of GSK Biologicals 2-dose inactivated hepatitis A vaccine when administered with a diphtheria, tetanus and pertussis combination (DTaP) vaccine and a Haemophilus influenza type B (Hib) vaccine in children 15 months of age. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

Timeline

Start
2003-11-11
Primary completion
2007-12-03
Completion
2007-12-03

Drugs

EvaluationDrugModalityDoseRoute
Subject ActHIB Vaccine Intramuscular
Subject Adacel Vaccine Intramuscular
Subject Havrix Vaccine Intramuscular